BlackRock Fund Advisors recently announced the acquisition of new stake in Ventyx Biosciences Inc (NASDAQ:VTYX). The institutional investor has increased its shareholding in the Healthcare company by 14.17% to 3.24 million shares with purchase of 0.4 million shares. This fresh investment now brings its stake to 5.49% valued currently at $7.0 million. In addition, Citadel Advisors LLC raised its holdings by 0.15 million to 2.93 million shares. And The Vanguard Group, Inc. has lifted its position by 11.79% or 0.27 million shares – to 2.54 million shares.
With over 3.78 million Ventyx Biosciences Inc (VTYX) shares trading Tuesday and a closing price of $2.36 on the day, the dollar volume was approximately $8.93 million. The shares have shown a negative half year performance of -92.62% and its price on 12/26/23 gained nearly 6.79%. Currently, there are 56.98M common shares owned by the public and among those 44.47M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 180 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 37 of these insider trades were purchases, accounting for 634,766 shares. Insider sales of the common stock occurred on 143 occasions, with total insider shares sold totaling 11,862,841 shares.
The top 3 mutual fund holders in Ventyx Biosciences Inc are American Funds Small Cap World Fu, T Rowe Price New Horizons Fund, and Vanguard Total Stock Market ETF. American Funds Small Cap World Fu owns 2.73 million shares of the company’s stock, all valued at over $5.89 million. T Rowe Price New Horizons Fund bought 72427.0 shares to see its total holdings expand to 1.72 million shares valued at over $3.72 million and representing 2.91% of the shares outstanding. Vanguard Total Stock Market ETF bought 0.18 million shares to bring its total holdings to over 1.61 million shares at a value of $3.47 million. Vanguard Total Stock Market ETF now owns shares totaling to 2.72% of the shares outstanding.
Shares of Ventyx Biosciences Inc (NASDAQ: VTYX) opened at $2.20, down -$0.01 from a prior closing price of $2.21. However, the script later moved the day high at 2.4100, up 6.79%. The company’s stock has a 5-day price change of 10.28% and -93.07% over the past three months. VTYX shares are trading -92.80% year to date (YTD), with the 12-month market performance down to -92.60% lower. It has a 12-month low price of $2.06 and touched a high of $47.25 over the same period. VTYX has an average intraday trading volume of 2.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.79%, -65.97%, and -91.40% respectively.
Institutional ownership of Ventyx Biosciences Inc (NASDAQ: VTYX) shares accounts for 74.11% of the company’s 56.98M shares outstanding. Mutual fund holders own 29.10%, while other institutional holders and individual stakeholders account for 47.50% and 26.61% respectively.
It has a market capitalization of $139.17M and a beta (3y monthly) value of -1.10. The earnings-per-share (ttm) stands at -$3.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.83% over the week and 6.93% over the month.
Analysts forecast that Ventyx Biosciences Inc (VTYX) will achieve an EPS of -$0.9 for the current quarter, -$0.87 for the next quarter and -$2.87 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.24 while analysts give the company a high EPS estimate of -$0.62. Comparatively, EPS for the current quarter was -$0.62 a year ago. Earnings per share for the fiscal year are expected to decrease by -62.27%, and 11.94% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate Ventyx Biosciences Inc (VTYX) as a “Moderate Buy” at a consensus score of 2.40. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 7 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the VTYX, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on November 07, 2023, with the firm’s price target at $77-$8.
